ArticleClinicoEconomics and outcomes research : CEOR2019

Value For Money In The Treatment Of Patients With Type 2 Diabetes Mellitus: Assessing The Long-Term Cost-Effectiveness Of IDegLira Versus iGlarLixi In Italy.

Johannes Pöhlmann et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.